Medicare Part D Payments for Generic Imatinib From 2017 to 2023
JAMA Internal Medicine · 2024
DOI: 10.1001/jamainternmed.2023.3932 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Internal Medicine, 2024. Verfasst von Stacie B Dusetzina. Beteiligte Einrichtung: Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee. Hauptthemen laut MEDLINE: Medicare Part D, Prescription Drugs. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This cross-sectional study compares pharmacy acquisition costs and point-of-sale prices for generic imatinib under Medicare Part D from 2017 to 2023.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee.
- Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
Zitieren
APA
Dusetzina, S. B. (2024). Medicare Part D Payments for Generic Imatinib From 2017 to 2023. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2023.3932
Vancouver
Dusetzina SB. Medicare Part D Payments for Generic Imatinib From 2017 to 2023. JAMA Internal Medicine. 2024. doi:10.1001/jamainternmed.2023.3932
BibTeX
@article{Dusetzina2024,
author = {Dusetzina, Stacie B},
title = {Medicare Part D Payments for Generic Imatinib From 2017 to 2023},
journal = {JAMA Internal Medicine},
year = {2024},
doi = {10.1001/jamainternmed.2023.3932}
}
EUVIMED